Reversible hepatotoxicity of paroxetine in a patient with major depression

C. Helmchen; R. J. Boerner; R. Meyendorf; U. Hegerl

doi:10.1055/s-2007-979576

Reversible hepatotoxicity of paroxetine in a patient with major depression

C. Helmchen^*, R. J. Boerner, R. Meyendorf, U. Hegerl

^*Corresponding author for this work

Ludwig-Maximilians-Universität

31 Citations (Scopus)

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are becoming widely used because of their favorable side-effect profile and their safety in overdose. We report about a patient with recurring major depression (DSM-IIIR) who was treated with paroxetine and developed a severe hepatotoxic reaction, which was reversed after withdrawal of the drug. Individual, patient-related causes for this side-effect were not found. To our knowledge, this is the first published case of a probably paroxetine-induced severe hepatotoxicity. Hepatotoxicity should be taken into account as a rare complication that may occur not only with tricyclic antidepressants (TCAs) but also with SSRIs.

Original language	English
Journal	Pharmacopsychiatry
Volume	29
Issue number	6
Pages (from-to)	223-226
Number of pages	4
ISSN	0176-3679
DOIs	https://doi.org/10.1055/s-2007-979576
Publication status	Published - 01.01.1996

Research Areas and Centers

Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1055/s-2007-979576

Cite this

@article{bd50ecb0eba2401fb1f88b5e6f866322,

title = "Reversible hepatotoxicity of paroxetine in a patient with major depression",

abstract = "Selective serotonin reuptake inhibitors (SSRIs) are becoming widely used because of their favorable side-effect profile and their safety in overdose. We report about a patient with recurring major depression (DSM-IIIR) who was treated with paroxetine and developed a severe hepatotoxic reaction, which was reversed after withdrawal of the drug. Individual, patient-related causes for this side-effect were not found. To our knowledge, this is the first published case of a probably paroxetine-induced severe hepatotoxicity. Hepatotoxicity should be taken into account as a rare complication that may occur not only with tricyclic antidepressants (TCAs) but also with SSRIs.",

author = "C. Helmchen and Boerner, \{R. J.\} and R. Meyendorf and U. Hegerl",

year = "1996",

month = jan,

day = "1",

doi = "10.1055/s-2007-979576",

language = "English",

volume = "29",

pages = "223--226",

journal = "Pharmacopsychiatry",

issn = "0176-3679",

publisher = "Georg Thieme Verlag",

number = "6",

}

TY - JOUR

T1 - Reversible hepatotoxicity of paroxetine in a patient with major depression

AU - Helmchen, C.

AU - Boerner, R. J.

AU - Meyendorf, R.

AU - Hegerl, U.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Selective serotonin reuptake inhibitors (SSRIs) are becoming widely used because of their favorable side-effect profile and their safety in overdose. We report about a patient with recurring major depression (DSM-IIIR) who was treated with paroxetine and developed a severe hepatotoxic reaction, which was reversed after withdrawal of the drug. Individual, patient-related causes for this side-effect were not found. To our knowledge, this is the first published case of a probably paroxetine-induced severe hepatotoxicity. Hepatotoxicity should be taken into account as a rare complication that may occur not only with tricyclic antidepressants (TCAs) but also with SSRIs.

AB - Selective serotonin reuptake inhibitors (SSRIs) are becoming widely used because of their favorable side-effect profile and their safety in overdose. We report about a patient with recurring major depression (DSM-IIIR) who was treated with paroxetine and developed a severe hepatotoxic reaction, which was reversed after withdrawal of the drug. Individual, patient-related causes for this side-effect were not found. To our knowledge, this is the first published case of a probably paroxetine-induced severe hepatotoxicity. Hepatotoxicity should be taken into account as a rare complication that may occur not only with tricyclic antidepressants (TCAs) but also with SSRIs.

UR - https://www.scopus.com/pages/publications/0029809175

U2 - 10.1055/s-2007-979576

DO - 10.1055/s-2007-979576

M3 - Journal articles

C2 - 8956353

AN - SCOPUS:0029809175

SN - 0176-3679

VL - 29

SP - 223

EP - 226

JO - Pharmacopsychiatry

JF - Pharmacopsychiatry

IS - 6

ER -

Reversible hepatotoxicity of paroxetine in a patient with major depression

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this